HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: MEN1-related pancreatic NETs: identification of unmet clinical needs and future directives
- PMID: 32069215
- DOI: 10.1530/ERC-19-0441
HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: MEN1-related pancreatic NETs: identification of unmet clinical needs and future directives
Abstract
The PanNET Working Group of the 16th International Multiple Endocrine Neoplasia Workshop (MEN2019) convened in Houston, TX, USA, 27-29 March 2019 to discuss key unmet clinical needs related to PanNET in the context of MEN1, with a special focus on non-functioning (nf)-PanNETs. The participants represented a broad range of medical scientists as well as representatives from patient organizations, pharmaceutical industry and research societies. In a case-based approach, participants addressed early detection, surveillance, prognostic factors and management of localized and advanced disease. For each topic, after a review of current evidence, key unmet clinical needs and future research directives to make meaningful progress for MEN1 patients with nf-PanNETs were identified. International multi-institutional collaboration is needed for adequately sized studies and validation of findings in independent datasets. Collaboration between basic, translational and clinical scientists is paramount to establishing a translational science approach. In addition, bringing clinicians, scientists and patients together improves the prioritization of research goals, assures a patient-centered approach and maximizes patient involvement. It was concluded that collaboration, research infrastructure, methodologic and reporting rigor are essential to any translational science effort. The highest priority for nf-PanNETs in MEN1 syndrome are (1) the development of a data and biospecimen collection architecture that is uniform across all MEN1 centers, (2) unified strategies for diagnosis and follow-up of incident and prevalent nf-PanNETs, (3) non-invasive detection of individual nf-PanNETs that have an increased risk of metastasis, (4) chemoprevention clinical trials driven by basic research studies and (5) therapeutic targets for advanced disease based on biologically plausible mechanisms.
Keywords: MEN1; conference proceeding; management; multiple endocrine neoplasia type 1; pancreatic neuroendocrine tumor; research infrastructure; risk stratification; surveillance; treatment; unmet clinical needs.
Similar articles
-
Expression of p27Kip1 and p18Ink4c in human multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors.J Endocrinol Invest. 2018 Jun;41(6):655-661. doi: 10.1007/s40618-017-0783-y. Epub 2017 Nov 13. J Endocrinol Invest. 2018. PMID: 29134609
-
What is the appropriate management of nonfunctioning pancreatic neuroendocrine tumours disclosed on screening in adult patients with multiple endocrine neoplasia type 1?Clin Endocrinol (Oxf). 2019 Dec;91(6):708-715. doi: 10.1111/cen.14094. Epub 2019 Oct 1. Clin Endocrinol (Oxf). 2019. PMID: 31505044 Review.
-
DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment.Eur J Endocrinol. 2018 Sep;179(3):153-160. doi: 10.1530/EJE-18-0195. Epub 2018 Jun 14. Eur J Endocrinol. 2018. PMID: 29903750
-
Prognostic value of WHO grade in pancreatic neuro-endocrine tumors in Multiple Endocrine Neoplasia type 1: Results from the DutchMEN1 Study Group.Pancreatology. 2017 Sep-Oct;17(5):766-772. doi: 10.1016/j.pan.2017.07.196. Epub 2017 Jul 31. Pancreatology. 2017. PMID: 28811081
-
Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.Endocr Relat Cancer. 2020 Jun;27(6):R145-R161. doi: 10.1530/ERC-19-0372. Endocr Relat Cancer. 2020. PMID: 32229700 Free PMC article.
Cited by
-
[Multiple neuroendocrine tumors of the pancreas].Pathologie (Heidelb). 2024 Feb;45(1):28-34. doi: 10.1007/s00292-023-01289-z. Epub 2024 Jan 5. Pathologie (Heidelb). 2024. PMID: 38180510 Review. German.
-
Plasma Polyamines as an Additional to Imaging Biomarker in MEN1 Patients With Duodenopancreatic Neuroendocrine Tumors.J Clin Endocrinol Metab. 2022 Jan 18;107(2):e880-e882. doi: 10.1210/clinem/dgab683. J Clin Endocrinol Metab. 2022. PMID: 34543418 Free PMC article. No abstract available.
-
Multiple Endocrine Neoplasia Type 1: Latest Insights.Endocr Rev. 2021 Mar 15;42(2):133-170. doi: 10.1210/endrev/bnaa031. Endocr Rev. 2021. PMID: 33249439 Free PMC article. Review.
-
Prognosis after surgery for multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors: Functionality matters.Surgery. 2021 Apr;169(4):963-973. doi: 10.1016/j.surg.2020.09.037. Epub 2020 Nov 19. Surgery. 2021. PMID: 33220975 Free PMC article.
-
A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression.J Clin Endocrinol Metab. 2021 Nov 19;106(12):e4969-e4980. doi: 10.1210/clinem/dgab554. J Clin Endocrinol Metab. 2021. PMID: 34318891 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials